| 複合語 | スコア |
|---|---|
| parkinson disease | 4873.9532875902 |
| motor symptoms | 274.92855969454 |
| diagnosis of parkinson disease | 131.1076379839 |
| nonmotor symptoms | 117.09629619592 |
| advanced parkinson disease | 92.360517132268 |
| dopamine agonists | 89.363274830466 |
| motor symptoms of parkinson | 78.553707474711 |
| deep-brain stimulation | 74.59684088845 |
| movement disorder society | 71.500218606488 |
| motor fluctuations | 63.689520441348 |
| management of parkinson disease | 56.006132917313 |
| early parkinson disease | 48.074220598332 |
| symptoms of parkinson disease | 44.183475729254 |
| parkinson disease psychosis | 43.793122353099 |
| motor symptoms of parkinson disease | 40.926595225105 |
| diagnostic criteria | 40.204427506014 |
| international parkinson | 40.165107725478 |
| mov disord | 38.875307273543 |
| advanced disease | 37.177109557799 |
| dopaminergic medications | 36.85007236267 |
| h time | 32.967457529573 |
| controlled trial | 32.76486247049 |
| disease progression | 30.122360469268 |
| red flags | 30.084824744691 |
| nonmotor symptoms of parkinson disease | 29.862232570191 |
| family history of parkinson disease | 29.129990989197 |
| dopamine therapy | 28.460498941515 |
| behavior disorder | 27.906971808138 |
| treatment of parkinson disease | 26.475911363772 |
| quality of life | 25.226892457611 |
| causes of parkinson disease | 25.065305441736 |
| clinical diagnosis of parkinson disease | 24.651882389253 |
| early symptoms of parkinson disease | 23.834767078921 |
| essential tremor | 23.354562846086 |
| symptoms of parkinsonism | 23.280814202913 |
| core motor symptoms | 22.953728061385 |
| mao-b inhibitors | 22.133638394006 |
| american academy of neurology | 21.955834260138 |
| health care | 21.534253083821 |
| mild parkinson disease | 21.414630753325 |
| vascular disease | 21.299725353165 |
| motor complications | 21.229840147116 |
| cause of parkinson disease | 20.871458184133 |
| parkinson disease medicines | 20.246777850204 |
| clinical diagnosis of parkinson | 19.980023098479 |
| urine storage symptoms | 19.946814328438 |
| et al | 19.798989873223 |
| parkinson disease exclusion criteria | 19.422733651409 |
| parkinson risk | 18.934013359849 |
| medical therapy | 18.914832180063 |
| rest tremor | 18.896333544557 |
| movement disorder society task force | 18.334321806849 |
| drug therapy | 18.18463954209 |
| alzheimer disease | 17.910862695365 |
| pathologic progression of parkinson disease | 17.612331327197 |
| pathogenesis of parkinson disease | 17.37931212307 |
| suspected parkinson disease | 17.37931212307 |
| gastrointestinal symptoms | 17.144642578193 |
| quality standards subcommittee | 16.754274167162 |
| nonmotor features of parkinson | 16.720012830768 |
| early parkinson fs disease | 16.607407763625 |
| non-motor symptoms of parkinson | 16.586227650737 |
| management of motor symptoms | 16.474967959271 |
| disease patients | 16.309275921902 |
| advanced parkinson fs disease | 16.11424380966 |
| many features of parkinson disease | 15.786666764889 |
| differential diagnosis of parkinson disease | 15.715064154396 |
| clinical parkinsonism | 15.640401453375 |
| progression of motor symptoms | 15.470883348849 |
| parkinson study group | 15.137044729979 |
| early motor complications | 14.996704033586 |
| formal diagnosis of parkinson disease | 14.938422933029 |
| orthostatic hypotension | 14.400822974714 |
| common neurodegenerative disorder | 14.005686295698 |
| evidence-based medicine review | 13.830348602001 |
| new onset parkinson disease | 13.321779770767 |
| motor system disorder | 13.055352029391 |
| sporadic parkinson fs disease | 13.021607304025 |
| specific symptoms | 12.688455161287 |
| mechanisms of parkinson | 12.661937868693 |
| movement-disorder neurologist | 12.585385134583 |
| adjunct therapy | 12.485374350864 |
| curr opin neurol | 12.446568035622 |
| n engl j med | 12.442410160626 |
| olfactory dysfunction | 12.354362477551 |
| primary outcome | 12.247448713916 |
| seppi k | 12.145481106843 |
| clinical practice | 12.055173868372 |
| other side effects | 11.975180662096 |
| prevalence of parkinson | 11.783260906255 |
| many patients | 11.695646941582 |
| physical therapy | 11.618950038622 |
| disease psychosis | 11.444022210305 |
| supportive criteria | 11.420262287518 |
| lancet neurol | 11.337800126734 |
| autonomic dysfunction | 11.018921819719 |
| braak h | 10.767126541911 |
| care excellence | 10.669676460234 |
| disease subcommittee | 10.649862676582 |
| unified parkinson | 10.647378163949 |
| direct pathologic effects of parkinson disease | 10.63546486221 |
| impulse control disorder | 10.305782432253 |
| emergence of motor symptoms | 10.224723453215 |
| recurrence of motor symptoms | 10.224723453215 |
| ongoing motor symptoms | 10.224723453215 |
| intrusion of motor symptoms | 10.224723453215 |
| delayed greemergent h tremor of parkinson disease | 9.8023335195667 |
| prevalence of parkinson disease increases | 9.7648279134894 |
| evidence-based review of management of motor symptoms | 9.7393028255346 |
| disease course | 9.6232372527296 |
| evidence of efficacy | 9.3905074804397 |
| hauser ra | 9.3613892772829 |
| facial expression | 9.3613892772829 |
| lang ae | 9.3613892772829 |
| progressive motor | 9.2767515810116 |
| common adverse effect | 9.2393419304495 |
| nat rev neurol | 9.1088741075542 |
| dopamine transporter | 8.9720926873273 |
| fox sh | 8.9442719099992 |
| lack of benefit | 8.7388518907318 |
| j neurol | 8.732101131047 |
| volkmann j | 8.6007539225133 |
| clinical history | 8.568349862833 |
| physical examination | 8.4519397417838 |
| atypical parkinsonism | 8.3648922729551 |
| premotor symptoms | 8.3494730511412 |
| common symptoms | 8.3494730511412 |
| adequate control of motor symptoms | 8.3150990581531 |
| cognitive impairment | 8.3026954513854 |
| balance symptoms | 8.1072009288422 |
| hard-to-control disease | 8.0921457089563 |
| wilson disease | 8.0921457089563 |
| tremor-predominant disease | 8.0921457089563 |
| disease duration | 8.0921457089563 |
| motor disability | 8.0655950722289 |
| mg of l-dopa | 8.0310685457409 |
| cognitive deficits | 7.7970979610547 |
| other gpremotor h symptoms | 7.7933519146605 |
| clinical diagnostic criteria | 7.7800168123931 |
| neuropathological assessment of parkinson | 7.6827219664325 |
| freezing of gait | 7.6673172509553 |
| sleep disorders | 7.6539711303027 |
| history of head trauma | 7.6517247310896 |
| katzenschlager r | 7.5446005780976 |
| mood symptoms | 7.5446005780976 |
| such nonmotor symptoms | 7.5389716958717 |
| motor skills | 7.5058819657661 |
| history of exposure | 7.4833147735479 |
| adjunct medications | 7.4448388728168 |
| contralateral side | 7.4448388728168 |
| core motor features | 7.4376249540514 |
| rapid clinical course | 7.4352798091322 |
| jenner p. non-motor features of parkinson disease | 7.388204267999 |
| national institutes of health | 7.2494296105731 |
| urinary symptoms | 7.2084342424043 |
| significant nonmotor symptoms | 7.1860294058534 |
| deep-brain stimulation group | 7.1718695814885 |
| clinical trial | 7.1680492684314 |
| mild cognitive impairment | 7.1450577591353 |
| dopamine agonist | 7.1352426900163 |
| concomitant sleep disorder | 7.0573495735677 |
| arch neurol | 7.0340079263114 |
| jama neurol | 7.0340079263114 |
| parkinson study group precept investigators | 7.0152924554953 |
| initial treatment | 6.9992710231612 |
| motor pathway | 6.7823299831253 |
| treatment of sleep disorders | 6.6412202171354 |
| risk factor | 6.6195018392937 |
| drug management | 6.5934915059146 |
| mood disorder | 6.5777363359721 |
| study group | 6.5777363359721 |
| dose of l-dopa | 6.5315739309452 |
| rapid eye movement sleep behavior disorder | 6.4632345829234 |
| side effect | 6.4474195909412 |
| diagnostic exclusion criteria | 6.4282549860643 |
| neurologic examination | 6.4021717458874 |
| new clinical diagnostic criteria | 6.3552561177301 |
| medication-refractory symptoms | 6.3442275806434 |
| bloem br | 6.3442275806434 |
| dopamine transporter imaging | 6.3376633710643 |
| cognitive decline | 6.3086842910598 |
| stepwise adjustment of parkinson medications | 6.2955545763877 |
| cholinesterase inhibitors | 6.2603383202932 |
| side effects | 6.2603383202932 |
| several motor outcomes | 6.2250291989976 |
| exclusion criteria | 6.1919769884393 |
| advanced deep-brain stimulation therapy | 6.1621435496555 |
| functional impairment | 6.160140576482 |
| exercise benefits motor | 6.0853816070709 |
| cognitive side effects | 6.0834628357098 |
| common gastrointestinal symptoms | 6.0409611796005 |
| chaudhuri kr | 6 |
| bilateral deep-brain stimulation | 5.9718951528454 |
| movement disorder society evidence-based medicine committee | 5.9686673280936 |
| homayoun h | 5.957892135529 |
| related disorders | 5.9436557324017 |
| atypical parkinsonian syndromes | 5.9235304387295 |
| catechol-o-methyl transferase inhibitors | 5.8833655068658 |
| immediate-release drug | 5.803009260803 |
| medication side effects | 5.7689982812296 |
| nontremor symptoms | 5.7326567532262 |
| positive symptoms | 5.7326567532262 |
| important side effect of dopamine agonists | 5.6574926690858 |
| progressive neurologic disorder | 5.6566240480853 |
| nonmotor complications | 5.6513218670805 |
| neurogenic orthostatic hypotension | 5.6420260246804 |
| medical history | 5.5950828130598 |
| presynaptic dopamine | 5.5836291546126 |
| adverse effects | 5.5663153674275 |
| initial use of dopamine agonists | 5.530171462735 |
| other gait disorders | 5.5131462990388 |
| lewy body dementia | 5.4989185479944 |
| ma j | 5.4953924101089 |
| reversible causes | 5.4216120216591 |
| medication-related motor complications | 5.4214586731343 |
| uncontrolled motor complications | 5.4214586731343 |
| recent-onset motor fluctuations | 5.4214586731343 |
| long-term motor complications | 5.4214586731343 |
| h periods | 5.3835632709553 |
| new diagnostic criteria | 5.3778905874053 |
| marek k | 5.3446902355676 |
| kieburtz k | 5.3446902355676 |
| adverse medication effects | 5.33433655068 |
| late manifestation of disease progression | 5.2945268929646 |
| national institute | 5.26429605181 |
| stern m | 5.26429605181 |
| coelho m | 5.26429605181 |
| good motor function | 5.259195040932 |
| restless leg syndrome | 5.2414827884178 |
| addition of dopamine agonists | 5.1854053341415 |
| removal of dopamine agonists | 5.1854053341415 |
| subthalamic nucleus | 5.1800401282227 |
| disease-modifying therapies | 5.1800401282227 |
| medical management | 5.1436867236104 |
| symptomatic management | 5.1436867236104 |
| general neurologist | 5.0914597900437 |
| disease rating scale | 5.0783090600187 |
| dopamine breakdown | 5.0453784915223 |
| bilateral stimulation | 5.0453784915223 |
| dopamine deficiency | 5.0453784915223 |
| precept study | 4.9979987988788 |
| prion disorder | 4.9979987988788 |
| tolerability of deep-brain stimulation therapy | 4.9795084648368 |
| postural tremor | 4.9737947036147 |
| dopaminergic goff h periods | 4.9541639996482 |
| practice parameter | 4.8989794855664 |
| isaacson s | 4.8989794855664 |
| idiopathic rem sleep behavior disorder | 4.8955667380178 |
| absence of nonmotor features | 4.8856589973663 |
| neurologist care | 4.8645985581956 |
| clinical outcomes | 4.8427346405845 |
| atypical neurodegenerative parkinsonism | 4.839811562999 |
| alternative diagnosis | 4.8205705136679 |
| formulations of l-dopa | 4.7753019278348 |
| secondary nonmotor neurodegenerative causes | 4.7451515679786 |
| gwearing-off h effect | 4.7398963239353 |
| neurodegenerative syndrome | 4.7381372205376 |
| atypical neurodegenerative parkinsonian disorders | 4.7184639854049 |
| oral immediate-release l-dopa | 4.7101756871628 |
| weintraub d | 4.6806946386414 |
| other medications | 4.6806946386414 |
| patient information | 4.6806946386414 |
| bilateral subthalamic stimulation | 4.6196709652247 |
| clinical presentation | 4.5799756509618 |
| dopaminergic therapies | 4.5590141139096 |
| zach h | 4.5270190558379 |
| reichmann h | 4.5270190558379 |
| h state | 4.5270190558379 |
| h period | 4.5270190558379 |
| h gsluggishness | 4.5270190558379 |
| bruschini h | 4.5270190558379 |
| williams h | 4.5270190558379 |
| moderate disease severity | 4.5242590318911 |
| poor sleep | 4.4609134425734 |
| long-acting dopaminergic drug | 4.4510182535424 |
| medication-induced dyskinesia | 4.4267276788013 |
| evidence-based review | 4.4267276788013 |
| quality-of-life scores | 4.4267276788013 |
| surgical interventions | 4.4267276788013 |
| weiner wj | 4.4267276788013 |
| pulsatile stimulation of dopamine receptors | 4.397983489376 |
| breathing sleep disorders | 4.3594283666312 |
| nighttime sleep disorders | 4.3594283666312 |
| atypical features | 4.3558771746929 |
| learned motor skills | 4.3030146004678 |
| perlmutter j | 4.3003769612566 |
| 123i-ioflupane dopamine transporter spect | 4.2988861033349 |
| nonmotor disability | 4.294076025711 |
| movement-disorder specialist | 4.2813902858562 |
| clinical setting | 4.2621475953544 |
| number of patients | 4.2621475953544 |
| absence of exclusion criteria | 4.2484406376281 |
| longitudinal study | 4.2027992734195 |
| double-blind study | 4.2027992734195 |
| placebo-controlled study | 4.2027992734195 |
| open-label study | 4.2027992734195 |
| rapid eye movement | 4.1854601371357 |
| globus pallidus interna | 4.1601676461038 |
| injectable dopamine agonist | 4.1601676461038 |
| quality-of-life score | 4.1195342878142 |
| troublesome dyskinesia | 4.1195342878142 |
| presence of bradykinesia | 4.1195342878142 |
| alternative diagnoses | 4.1195342878142 |
| differential diagnosis | 4.0536004644211 |
| exclusion criteria rules | 4.049546885517 |
| 123i-ioflupane dopamine transporter spect imaging | 4.0428232170799 |
| l-dopa doses | 4.0155342728704 |
| management of bladder dysfunction | 3.999837223024 |
| several years of l-dopa use | 3.9908790767727 |
| okun ms. deep-brain stimulation | 3.9600573257325 |
| cpn study group | 3.9405421141402 |
| earlystim study group | 3.9405421141402 |
| pd study group | 3.9405421141402 |
| special attention | 3.9359793425309 |
| brundin p | 3.9359793425309 |
| urinary incontinence | 3.9359793425309 |
| dopaminergic drugs | 3.9359793425309 |
| poewe w | 3.9359793425309 |
| timmermann l | 3.9359793425309 |
| typical parkinsonian gait | 3.9148676411689 |
| panicker j | 3.8858292384691 |
| schill j | 3.8858292384691 |
| fukasaka j | 3.8858292384691 |
| ferreira j | 3.8858292384691 |
| aharon-peretz j | 3.8858292384691 |
| send?n j | 3.8858292384691 |
| jankovic j | 3.8858292384691 |
| rau j | 3.8858292384691 |
| seibyl j | 3.8858292384691 |
| cummings j | 3.8858292384691 |
| health care professional | 3.8701091424451 |
| clinical findings | 3.8512851068431 |
| clinical guidelines | 3.8512851068431 |
| clinical efficiency | 3.8512851068431 |
| clinical relevance | 3.8512851068431 |
| drug administration | 3.8336586254776 |
| j neurol neurosurg psychiatry | 3.8321775894993 |
| early use | 3.8067540958393 |
| survival study | 3.7976578442319 |
| neurol clin | 3.7792667089114 |
| presence of parkinsonism | 3.7792667089114 |
| vascular parkinsonism | 3.7792667089114 |
| movement disorders emergencies | 3.7788985119798 |
| multidisciplinary care | 3.7606030930864 |
| balance therapy | 3.7606030930864 |
| agonist therapy | 3.7606030930864 |
| patients experience | 3.7511661226171 |
| nonergot dopamine agonists ropinirole | 3.7472768667293 |
| long-acting l-dopa | 3.7368757062242 |
| l-dopa regimen | 3.7368757062242 |
| several other pathologic conditions | 3.723629783182 |
| wearing-off effects | 3.7224194364084 |
| daytime hypersomnolence | 3.7224194364084 |
| diagnostic tool | 3.7224194364084 |
| ahlskog je | 3.7224194364084 |
| united states | 3.7224194364084 |
| good quality of life | 3.7062880231628 |
| irregular release of dopamine | 3.7062880231628 |
| hours of goff h time | 3.6852485896495 |
| alternate diagnosis | 3.6628415014847 |
| correct diagnosis | 3.6628415014847 |
| patient fs | 3.6628415014847 |
| accuracy of diagnosis | 3.6628415014847 |
| patients experience fluctuations | 3.6529276674218 |
| several medications | 3.6423205736757 |
| immediate-release formulations | 3.6002057436785 |
| early fluctuations | 3.6002057436785 |
| presynaptic dopaminergic system | 3.5953592505049 |
| new symptomatic therapies | 3.5953592505049 |
| adverse effect profile | 3.5953592505049 |
| cognitive function | 3.5840246342157 |
| formulations?oral extended-release l-dopa | 3.5345904677365 |
| vascular disorders | 3.5341188430494 |
| irreversible adverse effects | 3.5254687665352 |
| serious adverse effects | 3.5254687665352 |
| recent evidence-based review | 3.5254687665352 |
| other information | 3.4996355115806 |
| other medicines | 3.4996355115806 |
| parkinsonism relat disord | 3.4773390964968 |
| typical clinical presentation | 3.4747117108611 |
| intrajejunal infusion of l-dopa gel | 3.4708216345141 |
| base of gait | 3.4641016151377 |
| postuma rb | 3.4641016151377 |
| arm swings | 3.4641016151377 |
| halliday gm | 3.4641016151377 |
| minneap minn | 3.4641016151377 |
| kalia lv | 3.4641016151377 |
| first step | 3.4641016151377 |
| peripheral tissues | 3.4641016151377 |
| lim sy | 3.4641016151377 |
| holloway rg | 3.4641016151377 |
| gparkinsonism hyperpyrexia syndrome h | 3.4519247197843 |
| management advances | 3.4397906282504 |
| secondary parkinsonism | 3.4149529703483 |
| dream phase of sleep | 3.4142280776924 |
| good sleep hygiene | 3.4142280776924 |
| controlled-release l-dopa | 3.3766483753852 |
| sustained-release l-dopa | 3.3766483753852 |
| conversion of l-dopa | 3.3766483753852 |
| dopamine-blocking medications | 3.3635856610149 |
| multicenter controlled trial | 3.3604214537127 |
| early premotor | 3.3503689588345 |
| supportive therapy | 3.3437015248821 |
| disease-modifying treatment | 3.3437015248821 |
| early autonomic deficits | 3.3334377695972 |
| van hilten j | 3.3318160522188 |
| other conditions | 3.3097509196469 |
| international continence society | 3.3036235909394 |
| decreased quality of life | 3.3019272488946 |
| prolongation of medication effect | 3.3019272488946 |
| alternative cause of parkinsonism | 3.2706211157025 |
| pathologic changes | 3.2531531233956 |
| neuroprotective effect | 3.2237097954706 |
| future neurol | 3.1779718278113 |
| prominent tremor | 3.1779718278113 |
| front neurol | 3.1779718278113 |
| medication-refractory tremor | 3.1779718278113 |
| gastrointestinal tract | 3.1622776601684 |
| few patients | 3.1543421455299 |
| detailed history | 3.1463462836458 |
| thorough history | 3.1463462836458 |
| controlled trial of rasagiline | 3.14083560495 |
| somatic features of depression | 3.14083560495 |
| emergent essential tremor | 3.1364581089052 |
| dopaminergic projections | 3.1301691601466 |
| stepwise progression | 3.1301691601466 |
| dopaminergic blockers | 3.1301691601466 |
| enteral gel therapy | 3.1072325059539 |
| clinical slide set | 3.0956162091134 |
| complete lack of progression | 3.0861636884341 |
| andante study investigators | 3.0668124740328 |
| bilateral deep brain stimulation vs | 3.0514051588559 |
| proper sleep hygiene | 3.0417314178549 |
| other dopamine-blocking antipsychotic agents | 3.0350549753166 |
| pathologic involvement | 3.0274001040351 |
| refined criteria | 3.0274001040351 |
| mild depression | 3.0274001040351 |
| sufficient dose | 3.0274001040351 |
| mandatory criteria | 3.0274001040351 |
| early manifestation | 3.0274001040351 |
| exclusionary criteria | 3.0274001040351 |
| mao-b inhibitors selegiline | 3.0261714988458 |
| further gait deficits | 3.0182390421613 |
| increased risk | 2.9906975624424 |
| symptom control | 2.9906975624424 |
| new mixed mao-b inhibitor | 2.975475652329 |
| onset of movements | 2.9718278662008 |
| passive joint movement | 2.9595672453546 |
| treatment of anxiety | 2.9428309563827 |
| rapid-onset gait impairment | 2.9416827534329 |
| expert opin drug saf | 2.9278526754426 |
| sudden worsening of parkinsonism | 2.913792159502 |
| acute worsening of parkinsonism | 2.913792159502 |
| wearing-off time | 2.9129506302439 |
| double-blind trial | 2.9129506302439 |
| memory impairment | 2.9129506302439 |
| alterations of gait | 2.9129506302439 |
| secondary causes | 2.9129506302439 |
| medication regimen | 2.9129506302439 |
| effective medication | 2.9129506302439 |
| intestinal gel | 2.9129506302439 |
| lang a | 2.9129506302439 |
| red flags rules | 2.9041912218409 |
| autonomic function | 2.8925076085191 |
| physiol rev | 2.8925076085191 |
| intestinal gel formulations | 2.8844991406148 |
| equivalent dose of immediate-release carbidopa?l | 2.8777854609598 |
| lower-body parkinsonism | 2.8716217110259 |
| drug-induced parkinsonism | 2.8716217110259 |
| refractory tremor | 2.8716217110259 |
| symmetrical parkinsonism | 2.8716217110259 |
| current symptomatic therapies | 2.8536385282275 |
| effective symptomatic therapies | 2.8536385282275 |
| treated patients | 2.8502698827718 |
| elderly patients | 2.8502698827718 |
| individual patients | 2.8502698827718 |
| obstructive sleep apnea | 2.8429702849739 |
| stepwise assessment | 2.8284271247462 |
| further dose adjustment | 2.8210130123402 |
| immediate-release carbidopa-levodopa | 2.8173132472613 |
| immediate-release formulation | 2.8173132472613 |
| normal functional imaging | 2.8172691138478 |
| oral extended-release carbidopa?l | 2.7981664143395 |
| severe fluctuations | 2.7831576837137 |
| other genes | 2.7831576837137 |
| other considerations | 2.7831576837137 |
| vitamin d | 2.7831576837137 |
| other non?l | 2.7831576837137 |
| other doctors | 2.7831576837137 |
| common form of psychosis | 2.7494592739972 |
| clin drug investig | 2.7494592739972 |
| scheduled dose | 2.7355647997348 |
| early stages | 2.7355647997348 |
| last dose | 2.7355647997348 |
| low dose | 2.7355647997348 |
| reflexive eye movements | 2.7322193018926 |
| several medicines | 2.7232698153315 |
| standard surgical therapy | 2.7144176165949 |
| initial therapies | 2.7108060108295 |
| dopa gel | 2.7108060108295 |
| postural imbalance | 2.7108060108295 |
| postural reflexes | 2.7108060108295 |
| large subset of patients | 2.7098746210941 |
| early bulbar deficits | 2.7052932225631 |
| dopaminergic therapy?for example | 2.6960123091946 |
| recessive disorders | 2.6853496142827 |
| hypokinetic disorders | 2.6853496142827 |
| repetitive movements | 2.6853496142827 |
| patient fs reaction | 2.66716827534 |
| rescue therapy | 2.6591479484725 |
| known treatment | 2.6591479484725 |
| treatment of constipation | 2.6591479484725 |
| functional outcomes | 2.6591479484725 |
| urinary tract | 2.6591479484725 |
| nat rev neurosci | 2.6546748825543 |
| medication responsiveness | 2.632148025905 |
| antinausea medications | 2.632148025905 |
| medication-induced complications | 2.632148025905 |
| goal-directed behavior | 2.632148025905 |
| orthostatic lightheadedness | 2.632148025905 |
| rate of progression | 2.632148025905 |
| dopa medications | 2.632148025905 |
| common premotor symptom | 2.6207413942089 |
| alternative causes of imbalance | 2.6207413942089 |
| peak drug level | 2.6207413942089 |
| medical errors?may lead | 2.6153209720237 |
| complete neurologic examination | 2.6084654714896 |
| nat rev dis primers | 2.6018209830256 |
| physical function | 2.5900200641113 |
| extended-release formulation | 2.5900200641113 |
| atypical signs | 2.5900200641113 |
| extended-release carbidopa-levodopa | 2.5900200641113 |
| advanced stages | 2.5755095769014 |
| many years | 2.5457298950218 |
| health professionals | 2.5457298950218 |
| normal postural reflexes | 2.5423029068338 |
| increase risk | 2.5148668593659 |
| imaging test | 2.5148668593659 |
| medical education | 2.5148668593659 |
| number of steps | 2.5148668593659 |
| passive movements | 2.4989993994394 |
| cerebellar dysfunction | 2.4989993994394 |
| severe untreated depression | 2.4928828716784 |
| environmental risk factors | 2.4928828716784 |
| age-associated pathologic conditions | 2.4643818583473 |
| cubo e. new | 2.4494897427832 |
| presence of dementia | 2.4494897427832 |
| placebo group | 2.4494897427832 |
| presence of freezing | 2.4494897427832 |
| neuropsychiatric complications | 2.4494897427832 |
| concomitant depression | 2.4494897427832 |
| daily wearing-off time | 2.4494897427832 |
| schrag a | 2.4494897427832 |
| antipsychotic benefit | 2.4494897427832 |
| hur k | 2.4147364027664 |
| chi-burris k | 2.4147364027664 |
| sethi k | 2.4147364027664 |
| knudsen k | 2.4147364027664 |
| kochi k | 2.4147364027664 |
| hasegawa k | 2.4147364027664 |
| follett k | 2.4147364027664 |
| selective serotonin reuptake inhibitors | 2.4136903820681 |
| cochrane database syst rev | 2.4052058575179 |
| koller m | 2.3784142300054 |
| respiratory muscle | 2.3784142300054 |
| muscle tone | 2.3784142300054 |
| role of exercise | 2.3784142300054 |
| hellmich m | 2.3784142300054 |
| hallett m | 2.3784142300054 |
| murata m | 2.3784142300054 |
| stamelou m | 2.3784142300054 |
| systematic review | 2.3784142300054 |
| grundman m | 2.3784142300054 |
| politis m | 2.3784142300054 |
| detrusor muscle | 2.3784142300054 |
| munneke m | 2.3784142300054 |
| schootman m | 2.3784142300054 |
| assessment of safety | 2.3784142300054 |
| muscle weakness | 2.3784142300054 |
| balance changes | 2.3784142300054 |
| memory changes | 2.3784142300054 |
| stacy m | 2.3784142300054 |
| auffret m | 2.3784142300054 |
| severe postural instability | 2.376176797565 |
| several cellular mechanisms | 2.3672935308725 |
| braak e. staging of brain pathology | 2.3521580450494 |
| quality-of-life outcomes | 2.3403473193207 |
| pyramidal tract | 2.3403473193207 |
| multidisciplinary team | 2.3403473193207 |
| use of apomorphine | 2.3403473193207 |
| nervous system | 2.3403473193207 |
| protein intake | 2.3403473193207 |
| wheelchair use | 2.3403473193207 |
| fluid intake | 2.3403473193207 |
| normal muscle paralysis | 2.3299861015014 |
| generalized slowing of movements | 2.3201751253057 |
| autonomic functions | 2.3003266337912 |
| available therapies | 2.2795070569548 |
| one exclusion criterion | 2.2787044788325 |
| del tredici k | 2.2677220247015 |
| involuntary movements | 2.2581008643532 |
| erectile dysfunction | 2.2581008643532 |
| limb movements | 2.2581008643532 |
| amplitude of movements | 2.2581008643532 |
| extraocular movements | 2.2581008643532 |
| mitochondrial dysfunction | 2.2581008643532 |
| vestibular dysfunction | 2.2581008643532 |
| direction of movements | 2.2581008643532 |
| rhythm of movements | 2.2581008643532 |
| prior head trauma | 2.2449240966188 |
| disease-modifying drugs | 2.2360679774998 |
| multiple system atrophy | 2.2209061548523 |
| enough vitamin d | 2.2209061548523 |
| depression scales | 2.2133638394006 |
| regular exercise | 2.2133638394006 |
| practice improvement | 2.2133638394006 |
| fahn s | 2.2133638394006 |
| hsu a | 2.2133638394006 |
| finkbeiner s | 2.2133638394006 |
| proven efficacy | 2.2133638394006 |
| shown efficacy | 2.2133638394006 |
| jette n | 2.2133638394006 |
| frolkis a | 2.2133638394006 |
| perez-lloret s | 2.2133638394006 |
| reich s | 2.2133638394006 |
| fasano a | 2.2133638394006 |
| dopamine-refractory depression | 2.2133638394006 |
| eberly s | 2.2133638394006 |
| drapier s | 2.2133638394006 |
| gnonmotor fluctuations | 2.2133638394006 |
| quinn n | 2.2133638394006 |
| corbett a | 2.2133638394006 |
| cecere a | 2.2133638394006 |
| aldakheel a | 2.2133638394006 |
| levodopa adjunct | 2.2133638394006 |
| choudhry a | 2.2133638394006 |
| brice a | 2.2133638394006 |
| overeem s | 2.2133638394006 |
| kell s | 2.2133638394006 |
| efficacy of safinamide | 2.2133638394006 |
| lack of cost-effectiveness | 2.2133638394006 |
| ziemann a | 2.2133638394006 |
| device-related complications | 2.2133638394006 |
| lesage s | 2.2133638394006 |
| administration of botulinum toxin | 2.1822472719434 |
| uniform slowness of movements | 2.1685638970161 |
| several seconds | 2.165736770668 |
| several situations | 2.165736770668 |
| several options | 2.165736770668 |
| several weeks | 2.165736770668 |
| gronseth g | 2.1406951429281 |
| mild unsteadiness | 2.1406951429281 |
| many clinicians | 2.1406951429281 |
| neuroleptic malignant syndrome | 2.1398263878673 |
| u.k. national institute | 2.1398263878673 |
| cortical sensory loss | 2.1398263878673 |
| schrag a. psychosis | 2.1398263878673 |
| multidisciplinary team of clinicians | 2.1169328630255 |
| impaired attention | 2.1147425268811 |
| mills r | 2.1147425268811 |
| cortical signs | 2.1147425268811 |
| recent advances | 2.1147425268811 |
| number of persons | 2.1147425268811 |
| shimazu r | 2.1147425268811 |
| oakes d | 2.1147425268811 |
| silver d | 2.1147425268811 |
| constantinescu r | 2.1147425268811 |
| aarsland d | 2.1147425268811 |
| berg d | 2.1147425268811 |
| savica r | 2.1147425268811 |
| sakakibara r | 2.1147425268811 |
| recent studies | 2.1147425268811 |
| dano r | 2.1147425268811 |
| van der marck ma | 2.1039790110173 |
| 24-hour urine copper level | 2.0870738306761 |
| recent technologic advances | 2.0757816311124 |
| additional pertinent information | 2.0757816311124 |
| magnetic resonance imaging | 2.0757816311124 |
| limited oral intake | 2.0757816311124 |
| g?nier marchand d | 2.0757816311124 |
| physical therapist | 2.0597671439071 |
| neurobiol dis | 2.0597671439071 |
| bilateral lesions | 2.0597671439071 |
| placebo-controlled phase | 2.0597671439071 |
| substantia nigra | 2.0597671439071 |
| overactive bladder | 2.0597671439071 |
| ba f | 2.0597671439071 |
| poor mood | 2.0597671439071 |
| bladder infection | 2.0597671439071 |
| volume of speech | 2.0597671439071 |
| university of pittsburgh medical center | 2.0565711885958 |
| intraintestinal infusion of carbidopa?l | 2.0396489026555 |
| global life expectancy | 2.0396489026555 |
| barton b | 2 |
| glutamate-release inhibitor | 2 |
| dopamine-blocking properties | 2 |
| b isoform of monoamine oxidase | 2 |
| typical doses | 2 |
| parkinson-related psychosis | 2 |
| ravina b | 2 |
| longer-acting formulations | 2 |
| nalls ma | 2 |
| mena ma | 2 |
| neuroprotective role | 2 |
| cholinesterase inhibitor pyridostigmine | 2 |
| Ã 3-adrenergic agonist | 2 |
| vigorous exercise | 2 |
| first-in-human assessment of prx002 | 2 |
| multiple doses | 2 |
| unprovoked psychosis | 2 |
| off balance | 2 |
| anecdotal evidence | 2 |
| creese b | 2 |
| agid y. subthalamic neurostimulation | 1.9839302766304 |
| evening fluid intake | 1.9786024464679 |
| pyramidal tract sign | 1.9786024464679 |
| anticholinergic agents | 1.9679896712654 |
| available drugs | 1.9679896712654 |
| certain medicines | 1.9679896712654 |
| cerebellar signs | 1.9679896712654 |
| antinausea agents | 1.9679896712654 |
| cystoscopic injection of botulinum toxin | 1.9579730911015 |
| progressive supranuclear palsy | 1.9559811771959 |
| anticholinergic agent glycopyrrolate | 1.9441612972397 |
| antiepileptic agent zonisamide | 1.9441612972397 |
| olfactory deficit | 1.9343364202677 |
| loddo g | 1.9343364202677 |
| autoactivation deficits | 1.9343364202677 |
| olfactory bulb | 1.9343364202677 |
| annesi g | 1.9343364202677 |
| progressive decrements | 1.9343364202677 |
| mild nausea | 1.9343364202677 |
| giannini g | 1.9343364202677 |
| progressive aphasia | 1.9343364202677 |
| progressive speeding | 1.9343364202677 |
| calandra-buonaura g | 1.9343364202677 |
| deuschl g | 1.9343364202677 |
| akinetic rigid form | 1.9063685859939 |
| patient handouts | 1.8612097182042 |
| kenney c | 1.8612097182042 |
| vascular parkinsonism?characteristics | 1.8612097182042 |
| unintelligible speech | 1.8612097182042 |
| factor sa | 1.8612097182042 |
| modest benefit | 1.8612097182042 |
| weight loss | 1.8612097182042 |
| mg of carbidopa | 1.8612097182042 |
| additional carbidopa | 1.8612097182042 |
| variable expression | 1.8612097182042 |
| evanoff ba | 1.8612097182042 |
| few studies | 1.8612097182042 |
| healthy diet | 1.8612097182042 |
| rapid withdrawal | 1.8612097182042 |
| psychomotor slowing | 1.8612097182042 |
| speech pathologist | 1.8612097182042 |
| eggers c | 1.8612097182042 |
| troubling dyskinesia | 1.8612097182042 |
| houman homayoun | 1.8612097182042 |
| environmental factors | 1.8612097182042 |
| harris c | 1.8612097182042 |
| lots of water | 1.8612097182042 |
| copper deposits | 1.8612097182042 |
| v?rin m. pharmacological insights | 1.8612097182042 |
| vos ra | 1.8612097182042 |
| loss of motivation | 1.8612097182042 |
| clarke c | 1.8612097182042 |
| significant disability | 1.8612097182042 |
| various factors | 1.8612097182042 |
| ratchet-like resistance | 1.8612097182042 |
| duyckaerts c | 1.8612097182042 |
| zesiewicz t | 1.8612097182042 |
| dr. homayoun | 1.8612097182042 |
| frontotemporal dementia | 1.8612097182042 |
| late-onset dementia | 1.8612097182042 |
| initial monotherapy | 1.8612097182042 |
| single-photon emission | 1.8612097182042 |
| benefits of hypnotics | 1.8612097182042 |
| dietary modification | 1.8612097182042 |
| racette ba | 1.8612097182042 |
| projected number of people | 1.8493111942973 |
| substantia nigra pars | 1.8171205928321 |
| guttman m. effectiveness | 1.8171205928321 |
| positron emission tomography | 1.8171205928321 |
| major dietary restriction | 1.8171205928321 |
| eating lots of fiber | 1.8171205928321 |
| repetitive motion fatigue | 1.7817974362807 |
| lead pipe rigidity | 1.7817974362807 |
| such fine-motor tasks | 1.7817974362807 |
| marks wj jr | 1.7817974362807 |
| called lewy bodies | 1.7817974362807 |
| such structural abnormalities | 1.7817974362807 |
| ipx066 advance-pd investigators | 1.7817974362807 |
| short-term memory problems | 1.7817974362807 |
| variety of signs | 1.7782794100389 |
| close attention | 1.7782794100389 |
| zago w | 1.7782794100389 |
| grossardt br | 1.7782794100389 |
| multidisciplinary approach | 1.7782794100389 |
| krack p | 1.7782794100389 |
| bulk-forming agents | 1.7782794100389 |
| oertel w | 1.7782794100389 |
| normal perception | 1.7782794100389 |
| sambati l | 1.7782794100389 |
| appropriate drugs | 1.7782794100389 |
| severe dystonia | 1.7782794100389 |
| cortelli p | 1.7782794100389 |
| klingelhoefer l | 1.7782794100389 |
| longitudinal follow-up of swedd subjects | 1.7692284081335 |
| multicenter analysis of glucocerebrosidase mutations | 1.7692284081335 |
| slow prion-like pattern of spread | 1.7692284081335 |
| author thanks kelvin l. chou | 1.7411011265923 |
| caregiver stress | 1.7320508075689 |
| prominent unsteadiness | 1.7320508075689 |
| large meals | 1.7320508075689 |
| open-label results | 1.7320508075689 |
| caregiver burden | 1.7320508075689 |
| sufficient fiber | 1.7320508075689 |
| nursing home placement | 1.6983813295649 |
| regular bedtime routine | 1.6983813295649 |
| neurourology promotion committee | 1.6983813295649 |
| high-intensity resistance training | 1.6983813295649 |
| faulty protein degradation | 1.6983813295649 |
| unilateral presentation | 1.6817928305074 |
| reliable test | 1.6817928305074 |
| impaired performance | 1.6817928305074 |
| impaired language | 1.6817928305074 |
| multiple domains | 1.6817928305074 |
| sidransky e | 1.6817928305074 |
| prolonged periods | 1.6817928305074 |
| neuroprotective trials | 1.6817928305074 |
| pull test | 1.6817928305074 |
| daytime naps | 1.6817928305074 |
| corrective steps | 1.6817928305074 |
| ebersbach g. nonpharmacological treatments | 1.6817928305074 |
| united kingdom | 1.6817928305074 |
| increased susceptibility | 1.6817928305074 |
| stooped posture | 1.6817928305074 |
| diet modifications | 1.6817928305074 |
| absence of contraindications | 1.6817928305074 |
| later stages | 1.6817928305074 |
| posture holding | 1.6817928305074 |
| cortical regions | 1.6817928305074 |
| repetitive maneuvers | 1.6817928305074 |
| intestinal absorption | 1.6817928305074 |
| finazzi-agro e | 1.6817928305074 |
| excessive gambling | 1.6817928305074 |
| increased mortality | 1.6817928305074 |
| pesticide exposure | 1.6817928305074 |
| pathology of synucleinopathies | 1.6817928305074 |
| gasser t | 1.6817928305074 |
| additional testing | 1.6817928305074 |
| improved scores | 1.6817928305074 |
| urodynamic studies | 1.6817928305074 |
| excessive sleepiness | 1.6817928305074 |
| duda je | 1.6817928305074 |
| narrow base | 1.6817928305074 |
| excessive sedation | 1.6817928305074 |
| tool kit | 1.6817928305074 |
| pringsheim t | 1.6817928305074 |
| eyal e | 1.6817928305074 |
| professional organizations | 1.6817928305074 |
| shortened steps | 1.6817928305074 |
| anti-a-synuclein monoclonal antibody | 1.5874010519682 |
| unique challenges of dyskinesias | 1.5874010519682 |
| n-methyl-d-aspartate antagonist amantadine | 1.5874010519682 |
| corticobasal ganglionic degeneration | 1.5874010519682 |
| neutral amino acids | 1.5874010519682 |
| irresistible gsleep attacks | 1.5874010519682 |
| reduced stride length | 1.5874010519682 |
| sleep?wake cycle disruption | 1.5874010519682 |
| jansen steur en | 1.5874010519682 |
| norepinephrine prodrug droxidopa | 1.5874010519682 |
| low-hanging fruit of neurodegeneration | 1.5874010519682 |
| agricultural occupations | 1.5650845800733 |
| midbrain involvement | 1.5650845800733 |
| corti o | 1.5650845800733 |
| agricultural industry | 1.5650845800733 |
| economic burden | 1.5650845800733 |
| transdermal patch | 1.5650845800733 |
| fung vs | 1.5650845800733 |
| perlmutter js | 1.5650845800733 |
| healthy volunteers | 1.5650845800733 |
| neuropsychiatric issues | 1.5650845800733 |
| dorsey er | 1.5650845800733 |
| schapira ahv | 1.5650845800733 |
| high-protein meals | 1.5650845800733 |
| supine position | 1.5650845800733 |
| y?benes jg | 1.5650845800733 |
| gronseth gs | 1.5650845800733 |
| nursing homes | 1.5650845800733 |
| selective ¿ | 1.5650845800733 |
| kordower jh | 1.5650845800733 |
| hormonal disturbances | 1.5650845800733 |
| klostermann f | 1.5650845800733 |
| bower jh | 1.5650845800733 |
| mild-to-severe anxiety | 1.5650845800733 |
| rotigotine patch | 1.5650845800733 |
| zesiewicz ta | 1.5650845800733 |
| negative results | 1.5650845800733 |
| oxidative stress | 1.5650845800733 |
| certain things | 1.5650845800733 |
| mass lesions | 1.5650845800733 |
| metabolic disturbances | 1.5650845800733 |
| suchowersky o | 1.5650845800733 |
| current efforts | 1.5650845800733 |
| daily activities | 1.5650845800733 |
| outpatient setting | 1.5650845800733 |
| various strategies | 1.5650845800733 |
| supine hypertension | 1.5650845800733 |
| barbosa er | 1.5650845800733 |
| volume of voice | 1.5650845800733 |
| schapira ah | 1.5650845800733 |
| major source | 1.5650845800733 |
| computed tomography | 1.5650845800733 |
| neurobiol aging | 1.5650845800733 |
| slow pace | 1.5650845800733 |
| japan zonisamide | 1.5650845800733 |
| goldman jg | 1.5650845800733 |
| schuepbach wm | 1.4142135623731 |
| subdural hematoma | 1.4142135623731 |
| disease-specific biomarkers | 1.4142135623731 |
| therapeutic response | 1.4142135623731 |
| parkin mutation | 1.4142135623731 |
| dickson dw | 1.4142135623731 |
| vries nm | 1.4142135623731 |
| borm gf | 1.4142135623731 |
| monogenic causation | 1.4142135623731 |
| mental calculations | 1.4142135623731 |
| fernandez hh | 1.4142135623731 |
| nice guideline | 1.4142135623731 |
| whole grains | 1.4142135623731 |
| gallagher da | 1.4142135623731 |
| ben-shlomo y | 1.4142135623731 |
| upper extremities | 1.4142135623731 |
| neurosurgical approaches | 1.4142135623731 |
| second opinion | 1.4142135623731 |
| ophthalmologic referral | 1.4142135623731 |
| robottom bj | 1.4142135623731 |
| basal ganglia | 1.4142135623731 |
| u.s. food | 1.4142135623731 |
| espay aj | 1.4142135623731 |
| 4.6 hours | 1.4142135623731 |
| steeves td | 1.4142135623731 |
| visual misperceptions | 1.4142135623731 |
| aasly jo | 1.4142135623731 |
| polyethylene glycol | 1.4142135623731 |
| modified barium | 1.4142135623731 |
| full spectrum | 1.4142135623731 |
| formed hallucinations | 1.4142135623731 |
| populous nations | 1.4142135623731 |
| stowe rl | 1.4142135623731 |
| iacovelli v | 1.4142135623731 |
| rocca wa | 1.4142135623731 |
| willis aw | 1.4142135623731 |
| sullivan kl | 1.4142135623731 |
| griffith sg | 1.4142135623731 |
| bhatia kp | 1.4142135623731 |
| nocturnal polyuria | 1.4142135623731 |
| exception of quetiapine | 1.4142135623731 |
| high-compression stockings | 1.4142135623731 |
| heavy metals | 1.4142135623731 |
| odds ratio | 1.4142135623731 |
| r?b u | 1.4142135623731 |
| morgan jc | 1.4142135623731 |
| serum ceruloplasmin | 1.4142135623731 |
| neurourol urodyn | 1.4142135623731 |
| light touch | 1.4142135623731 |
| 4.8 hours | 1.4142135623731 |
| sexual activity | 1.4142135623731 |
| eszopiclone trazodone | 1.4142135623731 |
| standaert dg | 1.4142135623731 |
| gagnon jf | 1.4142135623731 |
| miyasaki jm | 1.4142135623731 |
| small vessel | 1.4142135623731 |
| off-label indication | 1.4142135623731 |
| hawker rj | 1.4142135623731 |
| dirkx mf | 1.4142135623731 |
| misfolded proteins | 1.4142135623731 |
| schenk db | 1.4142135623731 |
| plasma levels | 1.4142135623731 |
| fink gr | 1.4142135623731 |
| portable pump?have | 1.4142135623731 |
| valproic acid | 1.4142135623731 |
| ives nj | 1.4142135623731 |
| previous version | 1.4142135623731 |
| immediate reinstitution | 1.4142135623731 |
| production of neurotransmitters | 1.4142135623731 |
| focus of development | 1.4142135623731 |
| goetz cg | 1.4142135623731 |
| index finger | 1.4142135623731 |
| helmich rc | 1.4142135623731 |
| brandt md | 1.4142135623731 |
| mason ar | 1.4142135623731 |
| bie rma | 1.4142135623731 |
| 1-agonist midodrine | 1.4142135623731 |
| martin wr | 1.4142135623731 |
| potential candidates | 1.4142135623731 |
| salivary glands | 1.4142135623731 |
| jost wh | 1.4142135623731 |
| tanner cm | 1.4142135623731 |
| lozano am | 1.4142135623731 |
| social goals | 1.4142135623731 |
| enactment of dreams | 1.4142135623731 |
| axial mobility | 1.4142135623731 |
| systemic infections | 1.4142135623731 |
| normal-pressure hydrocephalus | 1.4142135623731 |
| korczyn ad | 1.4142135623731 |
| olanow cw | 1.4142135623731 |
| multistep turns | 1.4142135623731 |
| biglan km | 1.4142135623731 |
| incomplete penetrance | 1.4142135623731 |
| evaluation of candidacy | 1.4142135623731 |
| ffytche dh | 1.4142135623731 |
| inspiratory stridor | 1.4142135623731 |
| experimental models | 1.4142135623731 |
| vegetable picker | 1.4142135623731 |
| challenging cases | 1.4142135623731 |
| ness dk | 1.4142135623731 |
| neuronal injury | 1.4142135623731 |
| montplaisir jy | 1.4142135623731 |
| bertrand ja | 1.4142135623731 |
| antiemetic domperidone | 1.4142135623731 |
| frequent monitoring | 1.4142135623731 |
| weaver fm | 1.4142135623731 |
| kayser?fleischer rings | 1.4142135623731 |
| personal fees | 1.4142135623731 |
| recommendations of experts | 1.4142135623731 |
| similar antidepressants | 1.4142135623731 |
| thompson jp | 1.4142135623731 |
| integrated healthcare | 1.4142135623731 |
| intracytoplasmic inclusions | 1.4142135623731 |
| reward processing | 1.4142135623731 |
| mayo foundation | 1.4142135623731 |
| stool softeners | 1.4142135623731 |
| .0 b013e31822c9123 | 1 |
| .0 b013e3181d55f24 | 1 |
| 0.4 hour | 1 |
| .0 b013e318225ab66 | 1 |
American College of Physicians, Japan Chapter Cummunication Server